TREACE MEDICAL CONCEPTS INC
Treace Medical Concepts, Inc. (TMCI) is a US medical‑device company focused on surgical solutions for forefoot disorders, chiefly bunions (hallux valgus). Its flagship offering is the Lapiplasty® 3D Bunion Correction® procedure, plus instruments and implants designed to correct deformity in three planes rather than with traditional osteotomies. Investors should note a concentrated product portfolio, ongoing efforts to expand surgeon training and reimbursement, and a market capitalisation of about $439.05M that places TMCI in the small‑cap growth category. Opportunities include broader clinical adoption, geographic expansion and potential product extensions, while risks include competition, reimbursement pressures, regulatory developments and the typical capital needs of growing medtech companies. Financial performance in this sector can be lumpy and share prices may be volatile. This summary is educational and not personalised investment advice; suitability depends on individual circumstances and investors should review company filings and speak to a financial adviser.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Treace Medical's stock, with a target price indicating slight growth potential.
Financial Health
TREACE MEDICAL CONCEPTS INC is performing well with strong profits, revenue, and cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring TMCI
Healthcare's Compliance Catalyst
The Department of Justice's investigation into UnitedHealth's billing practices is increasing pressure on the entire healthcare industry to ensure compliance. This regulatory focus creates an investment opportunity in companies that provide specialized technology for transparent and accurate medical billing.
Published: July 26, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Adoption‑driven growth
Revenue potential depends on wider surgeon adoption and training programmes, though uptake can be gradual and performance may vary.
Clinical evidence focus
Clinical studies support 3D correction outcomes, which can aid payer acceptance, but continued data and long‑term results matter.
Addressable market size
An ageing population and high prevalence of forefoot conditions present an opportunity, yet competition and reimbursement are important constraints.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
